UK Vision Strategy claims sight loss is set to double

Article

Sight loss could double in the UK by the year 2050, according to predictions from eye health service UK Vision Strategy.

Sight loss could double in the UK by the year 2050, according to predictions from eye health service UK Vision Strategy.

Currently, one in five people aged 75 years and above have developed sight loss, compared to one in two people aged 90 years and above. Experts from the eye care and sight loss divisions are planning to identify improvements in diagnosis and find better treatments to avoid the predicted significant increase.

The UK Vision Strategy is a segment of the World Health Organisation's VISION 2020 initiative, which aspires to eliminate sight loss by the year 2020.

Chairperson of the UK Vision UK Vision Strategy and Chief Executive of Royal National Institute of Blind People, Lesley-Anne Alexander said, "Looking after your eyes by having regular checks is just as important as monitoring your blood pressure or paying a routine visit to the dentist. Problem teeth can usually be repaired or replaced but with eyes, the solution is rarely so simple. Whatever your age or health situation, if you haven't had your eyes checked recently, take action now and you could well prevent sight loss problems in later life".

Chairperson of VISION 2020 UK Nick Astbury, said, " Losing your sight should never become a naturally accepted part of getting older. Over half of all sight loss in this country can be avoided if it is picked up early and treated. Taking regular exercise, eating a healthy diet and stopping smoking is also vital for keeping your eyes healthy".

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.